IPSEN (OTCMKTS:IPSEY) Shares Down 6.2% – What’s Next?

IPSEN (OTCMKTS:IPSEY)’s stock price was down 6.2% on Tuesday . The company traded as low as $44.74 and last traded at $44.74. 256 shares were traded during mid-day trading, a decline of 88% from the average session volume of 2,197 shares. The stock had previously closed at $47.72.

Analysts Set New Price Targets

IPSEY has been the subject of several recent analyst reports. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. HC Wainwright reissued a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, IPSEN has an average rating of “Hold”.

IPSEN Price Performance

The company has a 50-day simple moving average of $47.03 and a 200-day simple moving average of $44.62.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).